JP2009530413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530413A5 JP2009530413A5 JP2009501667A JP2009501667A JP2009530413A5 JP 2009530413 A5 JP2009530413 A5 JP 2009530413A5 JP 2009501667 A JP2009501667 A JP 2009501667A JP 2009501667 A JP2009501667 A JP 2009501667A JP 2009530413 A5 JP2009530413 A5 JP 2009530413A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- composition
- methyl
- adenosine receptor
- trihydropurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78357506P | 2006-03-17 | 2006-03-17 | |
| US60/783,575 | 2006-03-17 | ||
| PCT/US2007/064182 WO2007109547A2 (en) | 2006-03-17 | 2007-03-16 | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012268193A Division JP2013049719A (ja) | 2006-03-17 | 2012-12-07 | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009530413A JP2009530413A (ja) | 2009-08-27 |
| JP2009530413A5 true JP2009530413A5 (enExample) | 2011-03-03 |
| JP5250848B2 JP5250848B2 (ja) | 2013-07-31 |
Family
ID=38514256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501667A Active JP5250848B2 (ja) | 2006-03-17 | 2007-03-16 | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
| JP2012268193A Pending JP2013049719A (ja) | 2006-03-17 | 2012-12-07 | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012268193A Pending JP2013049719A (ja) | 2006-03-17 | 2012-12-07 | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7795268B2 (enExample) |
| EP (1) | EP1996201A2 (enExample) |
| JP (2) | JP5250848B2 (enExample) |
| KR (1) | KR101428113B1 (enExample) |
| CN (1) | CN101405003B (enExample) |
| AU (1) | AU2007227021B2 (enExample) |
| CA (2) | CA2646333C (enExample) |
| IL (1) | IL194158A0 (enExample) |
| MX (1) | MX2008011828A (enExample) |
| NO (1) | NO20083968L (enExample) |
| NZ (1) | NZ571324A (enExample) |
| RU (1) | RU2457842C2 (enExample) |
| WO (1) | WO2007109547A2 (enExample) |
| ZA (1) | ZA200807894B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US20080194593A1 (en) * | 2001-11-09 | 2008-08-14 | Rao Kalla | A2b adenosine receptor antagonists |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| EP2311462A1 (en) | 2004-10-15 | 2011-04-20 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| US7598379B2 (en) * | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| CA2646333C (en) | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| WO2009055021A1 (en) * | 2007-10-26 | 2009-04-30 | New York University School Of Medicine | Methods and compositions for treating hepatic diseases |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| BRPI1009398A2 (pt) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
| EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| EP2616470B1 (en) | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| US20140142113A1 (en) * | 2012-11-09 | 2014-05-22 | Michael W. Burnet | Method of treating inflammatory diseases using adenosine 2b receptor antagonists |
| US10583102B2 (en) | 2014-10-06 | 2020-03-10 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
| WO2016129760A1 (ko) * | 2015-02-13 | 2016-08-18 | 한국과학기술원 | Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물 |
| KR101666605B1 (ko) | 2015-02-13 | 2016-10-18 | 한국과학기술원 | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물 |
| CA3001543C (en) | 2015-10-29 | 2023-06-27 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| EP3414319B1 (en) | 2016-02-10 | 2024-07-24 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
| KR101709307B1 (ko) | 2016-10-31 | 2017-02-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물 |
| CN110636846B (zh) * | 2017-05-17 | 2023-05-16 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的喹唑啉吡唑衍生物 |
| JP2020532541A (ja) | 2017-08-31 | 2020-11-12 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法 |
| JP7849948B2 (ja) * | 2018-03-05 | 2026-04-22 | テオン セラピューティクス，インク． | アデノシン受容体アンタゴニストおよびその使用 |
| GB201804922D0 (en) | 2018-03-27 | 2018-05-09 | Ucl Business Plc | Traatment |
| AU2019312296B2 (en) * | 2018-07-27 | 2025-05-29 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| CN111686239B (zh) * | 2019-03-11 | 2021-12-24 | 中国科学院微生物研究所 | 抗真菌化合物的应用 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| AU2002359365B2 (en) * | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| ES2208063B1 (es) * | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| MXPA04000908A (es) * | 2002-05-30 | 2004-03-26 | King Pharmaceuticals Res & Dev | Compuestos farmaceuticamente activos que tienen estructura de anillo de pirazolotriazolopirimidina triciclica y metodos de uso. |
| WO2004086052A2 (en) | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b) |
| GB0401336D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| CA2646333C (en) | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
-
2007
- 2007-03-16 CA CA2646333A patent/CA2646333C/en active Active
- 2007-03-16 CN CN2007800095071A patent/CN101405003B/zh active Active
- 2007-03-16 US US11/687,236 patent/US7795268B2/en active Active
- 2007-03-16 MX MX2008011828A patent/MX2008011828A/es active IP Right Grant
- 2007-03-16 RU RU2008137279/15A patent/RU2457842C2/ru active
- 2007-03-16 EP EP07758704A patent/EP1996201A2/en not_active Withdrawn
- 2007-03-16 WO PCT/US2007/064182 patent/WO2007109547A2/en not_active Ceased
- 2007-03-16 CA CA2849661A patent/CA2849661A1/en not_active Abandoned
- 2007-03-16 JP JP2009501667A patent/JP5250848B2/ja active Active
- 2007-03-16 KR KR1020087022707A patent/KR101428113B1/ko active Active
- 2007-03-16 AU AU2007227021A patent/AU2007227021B2/en active Active
- 2007-03-16 NZ NZ571324A patent/NZ571324A/en unknown
-
2008
- 2008-09-15 ZA ZA200807894A patent/ZA200807894B/xx unknown
- 2008-09-17 NO NO20083968A patent/NO20083968L/no not_active Application Discontinuation
- 2008-09-17 IL IL194158A patent/IL194158A0/en unknown
-
2010
- 2010-08-10 US US12/853,510 patent/US8188099B2/en active Active
-
2012
- 2012-02-28 US US13/407,616 patent/US8609671B2/en active Active
- 2012-12-07 JP JP2012268193A patent/JP2013049719A/ja active Pending
-
2013
- 2013-10-04 US US14/046,847 patent/US20140243358A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008137279A (ru) | Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина а2в | |
| CN103096881B (zh) | 含有具有不愉快味道的药物的膜制剂 | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| JP2022009090A5 (enExample) | ||
| JP2018507914A5 (enExample) | ||
| JP2018514534A5 (enExample) | ||
| US20190216779A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| JP2009102342A5 (enExample) | ||
| FI3735295T3 (fi) | Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon | |
| JP2008540672A (ja) | 病状に起因する性的機能不全の治療方法 | |
| JP2015524444A5 (enExample) | ||
| JP2019503365A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2010503695A5 (enExample) | ||
| IL314360A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2010121128A3 (en) | Compositions and methods for treating or inhibiting liver injury | |
| NZ582089A (en) | Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir | |
| JP2023504415A5 (enExample) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2024533756A5 (enExample) | ||
| ES2973583T3 (es) | Regímenes de administración asociados a las formulaciones inyectables de paliperidona de liberación prolongada | |
| JP2013518124A5 (enExample) |